JP5752359B2 - 体重増加抑制組成物及びこれを含む食品 - Google Patents
体重増加抑制組成物及びこれを含む食品 Download PDFInfo
- Publication number
- JP5752359B2 JP5752359B2 JP2010040502A JP2010040502A JP5752359B2 JP 5752359 B2 JP5752359 B2 JP 5752359B2 JP 2010040502 A JP2010040502 A JP 2010040502A JP 2010040502 A JP2010040502 A JP 2010040502A JP 5752359 B2 JP5752359 B2 JP 5752359B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weight gain
- inhibiting
- component
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002401 inhibitory effect Effects 0.000 title claims description 76
- 239000000203 mixture Substances 0.000 title claims description 47
- 235000019786 weight gain Nutrition 0.000 title claims description 47
- 230000004584 weight gain Effects 0.000 title claims description 40
- 235000013305 food Nutrition 0.000 title description 9
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 28
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 28
- 230000015572 biosynthetic process Effects 0.000 claims description 27
- 238000003786 synthesis reaction Methods 0.000 claims description 27
- 239000000284 extract Substances 0.000 claims description 24
- 150000002632 lipids Chemical class 0.000 claims description 21
- 241000545263 Salacia <hydroid> Species 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 241000196324 Embryophyta Species 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 230000001629 suppression Effects 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 102000008186 Collagen Human genes 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 10
- 229920001436 collagen Polymers 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 9
- 239000000419 plant extract Substances 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 7
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 claims description 7
- 102400000472 Sucrase Human genes 0.000 claims description 7
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 claims description 7
- 235000011073 invertase Nutrition 0.000 claims description 7
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 241000251468 Actinopterygii Species 0.000 claims description 5
- 229930013686 lignan Natural products 0.000 claims description 5
- 150000005692 lignans Chemical class 0.000 claims description 5
- 235000009408 lignans Nutrition 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 241000207961 Sesamum Species 0.000 claims 1
- 239000000843 powder Substances 0.000 description 11
- 240000000249 Morus alba Species 0.000 description 7
- 235000008708 Morus alba Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 244000040738 Sesamum orientale Species 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000019688 fish Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000208251 Gymnema Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000508269 Psidium Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 244000098338 Triticum aestivum Species 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 2
- 244000061508 Eriobotrya japonica Species 0.000 description 2
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 2
- 244000004281 Eucalyptus maculata Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 241000269908 Platichthys flesus Species 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- SOWRVDSZMRPKRG-YRPOCYRVSA-N S(=O)(=O)(O[C@@H](CO)[C@@H](C[S@+]1[C@@H]([C@H]([C@@H](C1)O)O)CO)O)[O-] Chemical compound S(=O)(=O)(O[C@@H](CO)[C@@H](C[S@+]1[C@@H]([C@H]([C@@H](C1)O)O)CO)O)[O-] SOWRVDSZMRPKRG-YRPOCYRVSA-N 0.000 description 2
- 244000087020 Salacia prinoides Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 2
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- -1 cotaranol Chemical compound 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000003230 hygroscopic agent Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 229960001729 voglibose Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241001504226 Hoodia Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000134253 Lanka Species 0.000 description 1
- 235000003956 Luffa Nutrition 0.000 description 1
- 244000050983 Luffa operculata Species 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000647991 Salacia reticulata Species 0.000 description 1
- 240000004794 Sanchezia nobilis Species 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 244000058639 Stephania reticulata Species 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241001222097 Xenocypris argentea Species 0.000 description 1
- OMKXVFDVAGCPBS-GTEYUELZSA-N [(2s,3s,4r,5r,6s)-1-[(2r,3s,4s)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]-2,4,5,6,7-pentahydroxyheptan-3-yl] sulfate Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](OS([O-])(=O)=O)[C@H](O)C[S+]1C[C@@H](O)[C@H](O)[C@H]1CO OMKXVFDVAGCPBS-GTEYUELZSA-N 0.000 description 1
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 description 1
- 229930185474 acteoside Natural products 0.000 description 1
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000017277 hoodia Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000007058 regulation of lipid biosynthetic process Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
特許文献2には、フーディア・ゴードニー、コムギ抽出物、キノコキトサン、おからなどを含む肥満及び生活習慣病の予防・改善をするための健康食品用組成物が開示されている。
特許文献3には、サラシア・レティキュラータ葉の抽出物等を含むリパーゼ活性阻害剤が開示されており、膵リパーゼの活性を強く阻害することで効果的でかつ安全に、肥満や高脂血症を予防および治療改善できると記載されている。
[1] α−グルコシダーゼ活性阻害成分と、脂質合成阻害成分と、を含む体重増加抑制組成物であって、前記α−グルコシダーゼ活性阻害成分がサラシア属植物抽出物であり、前記脂質合成阻害成分が海洋動物性ペプチド及びゴマリグナンからなる群より選択される少なくとも1つであり、前記海洋動物性ペプチドが海水魚のコラーゲン組織から抽出したコラーゲンペプチドである、体重増加抑制組成物。
[2] 前記脂質合成阻害成分の含有量が、α−グルコシダーゼ活性阻害成分の全質量の0.005倍量〜200倍量である[1]に記載の体重増加抑制組成物。
[3] 前記α−グルコシダーゼ活性阻害成分の含有量が、組成物全質量の99質量%〜0.0001質量%である[1]又は[2]に記載の体重増加抑制組成物。
[4] 前記脂質合成阻害成分の含有量が、組成物全質量の99質量%〜0.0001質量%である[1]〜[3]のいずれかに記載の体重増加抑制組成物。
[5] 前記α−グルコシダーゼ活性阻害成分のスクラーゼ50%阻害濃度(IC50値)が、0.0001μg/ml以上800μg/ml以下である[1]〜[4]のいずれかに記載の体重増加抑制組成物。
[6] 前記サラシア属植物抽出物が、抽出溶媒として熱水、エタノール又は含水アルコールを用いて抽出することによって得られるサラシア属植物抽出物である[1]〜[5]のいずれかに記載の体重増加抑制組成物。
[7] [1]〜[6]のいずれかに記載の体重増加抑制組成物を含有する食品。
但し、本発明の体重増加抑制組成物は、α−グルコシダーゼ活性阻害成分としてサラシア属植物抽出物を適用し、脂質合成阻害成分として、海洋動物性ペプチド及びゴマリグナンからなる群より選択される少なくとも1つを適用する。また、海洋動物性ペプチドとしては、海水魚のコラーゲン組織から抽出したコラーゲンペプチドを適用する。
本発明の体重増加抑制組成物は、α−グルコシダーゼ活性阻害成分と、脂質合成阻害成分とを含むので、生体内における脂肪の分解が促進されると共に、脂肪の合成も阻害され、より効果的に体重の増加を抑制することができる。即ち、本発明は、α−グルコシダーゼ活性阻害成分に脂肪分解促進作用があるとの知見に基づき、また、脂質合成阻害成分と組み合わせた場合に、より顕著に体重の増加を抑制することを見出したものである。
本明細書において「〜」を用いて示された数値範囲は、「〜」の前後に記載される数値をそれぞれ最小値及び最大値として含む範囲を示す。
本発明において、各成分の量について言及する場合、各成分が複数存在する場合には、単独であることを特に断らない限り、存在する複数の成分の合計量を意味する。
以下、本発明について説明する。
これらは、化学合成品であってもよいが、天然物の粉砕物または抽出物の形態で用いられることが好ましい。なお、サラシア属植物の抽出物である場合には、熱水抽出物であってもアルコール抽出物であってもよい。
これらは単独で使用してもよく、2種以上を組み合わせて使用してもよい。
ここで、海洋動物性ペプチドとして、魚類(海水魚)のコラーゲン組織から抽出したコラーゲンが挙げられ、コラーゲンの原料としては、例えば、マグロ(キハダ)、サメ、タラ、ヒラメ、カレイ、タイ、テラピア、サケ等の皮が挙げられる。
溶液状とする場合に好ましく用いられる担体としては水等の水性媒体を挙げることができる。固形状にするために好ましく用いられる添加成分としては、結晶セルロース、ステアリン酸マグネシウムのような賦形剤、コーンスターチ、アルギン酸のような膨化剤を用いることができる。また、錠剤、カプセル剤、顆粒剤の被覆剤として、シェラックや砂糖、フイルムコーティング基材、イーストラップ等を用いることができる。
本発明にかかる食品は、体重増加抑制組成物を含有するものであればよく、体重増加抑制組成物に関する事項が、本発明の食品においてもそのまま適用可能である。
本発明にかかる食品における体重増加抑制組成物の含有量は、体重増加抑制組成物の効果が得られる範囲であればよく、例えば、0.001質質量%以上含有されていればよい。
なお、実施例1、及び実施例2における試料I及び試料J以外の試料については、参考試料とする。
α−グルコシダーゼ活性阻害成分が脂肪分解を促進することについて、以下のように、確認した。
サラシアエキス末は、サラシア・レチキュラータ(S. reticulata)とサラシア・オブロンガ(S. oblonga)の根及び幹の部分を粉砕後、98℃の熱水抽出工程を経て得られた液をスプレー乾燥して調製した。
桑葉抽出物は、桑葉乾燥粉末300gに1リットルの25%(v/v)エタノールを加えて抽出し、ろ液を減圧下脱溶媒して乾燥して調製した。
トウチエキスは、市販のトウチをフリーズドライして粉末化したものを使用した。
これらの3種の有効成分を含む試料についてはスクラーゼIC50を調べたところ、いずれのスクラーゼIC50も450μg/ml以下であることを確認した。
30日の摂取期間後に、採血を行い、定法に従って血清を分離し、血清中の中性脂肪量を測定した。結果を表1に示す。
高脂肪食のみよりも血清中中性脂肪が有意に減少したものを下記の実施例2に供した。
次に実施例1で用いたサラシア属植物抽出物、桑葉エキス、トウチエキスと、表2に記載の各種脂質合成阻害成分とを組み合わせた試料を用いて、体重の増加抑制を以下のように評価した。
高脂肪食(HFD32、日本クレア社製)を30日間飼育した8週齢のオスのSDラット(を7匹ずつの群に分け、それぞれ体重を測定した後に、給餌を継続させながら、表2に記載の組成の試料を、胃ゾンデを用いて30日間摂取させた。対照群には注射用水のみを投与した。
30日間投与後に、体重を測定した。結果を表2に示す。表2中の各成分の量は一日あたりの投与量である。
特に、α−グルコシダーゼ活性阻害成分としてサラシア属植物抽出物を使用し、脂質合成阻害成分としてゴマリグナン、海洋動物性ペプチドを使用した組み合わせにおいて、特に大きな体重増加抑制効果が得られることがわかった(試料I、J)。
Claims (7)
- α−グルコシダーゼ活性阻害成分と、脂質合成阻害成分と、を含む体重増加抑制組成物であって、前記α−グルコシダーゼ活性阻害成分がサラシア属植物抽出物であり、前記脂質合成阻害成分が海洋動物性ペプチド及びゴマリグナンからなる群より選択される少なくとも1つであり、前記海洋動物性ペプチドが海水魚のコラーゲン組織から抽出したコラーゲンペプチドである、体重増加抑制組成物。
- 前記脂質合成阻害成分の含有量が、α−グルコシダーゼ活性阻害成分の全質量の0.005倍量〜200倍量である請求項1に記載の体重増加抑制組成物。
- 前記α−グルコシダーゼ活性阻害成分の含有量が、組成物全質量の99質量%〜0.0001質量%である請求項1又は請求項2に記載の体重増加抑制組成物。
- 前記脂質合成阻害成分の含有量が、組成物全質量の99質量%〜0.0001質量%である請求項1〜請求項3のいずれか1項に記載の体重増加抑制組成物。
- 前記α−グルコシダーゼ活性阻害成分のスクラーゼ50%阻害濃度(IC50値)が、0.0001μg/ml以上800μg/ml以下である請求項1〜請求項4のいずれか1項に記載の体重増加抑制組成物。
- 前記サラシア属植物抽出物が、抽出溶媒として熱水、エタノール又は含水アルコールを用いて抽出することによって得られるサラシア属植物抽出物である請求項1〜請求項5のいずれか1項に記載の体重増加抑制組成物。
- 請求項1〜請求項6のいずれか1項に記載の体重増加抑制組成物を含有する食品。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010040502A JP5752359B2 (ja) | 2010-02-25 | 2010-02-25 | 体重増加抑制組成物及びこれを含む食品 |
KR1020127016198A KR20120123036A (ko) | 2010-02-25 | 2010-12-03 | 체중 증가 억제 조성물 및 이를 함유하는 식품 |
CN2010800591321A CN102711832A (zh) | 2010-02-25 | 2010-12-03 | 体重增加抑制组合物及含有其的食品 |
PCT/JP2010/071743 WO2011104971A1 (ja) | 2010-02-25 | 2010-12-03 | 体重増加抑制組成物及びこれを含む食品 |
US13/519,997 US20120276081A1 (en) | 2010-02-25 | 2010-12-03 | Body weight gain suppressing composition and food product comprising the same |
EP10846634.3A EP2540316A4 (en) | 2010-02-25 | 2010-12-03 | WEIGHT GAIN CONTROL COMPOSITION AND FOOD PRODUCT INCLUDING THE SAME |
US14/185,129 US20140186331A1 (en) | 2010-02-25 | 2014-02-20 | Body Weight Gain Suppresing Composition and Food Product Comprising the Same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010040502A JP5752359B2 (ja) | 2010-02-25 | 2010-02-25 | 体重増加抑制組成物及びこれを含む食品 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011173847A JP2011173847A (ja) | 2011-09-08 |
JP5752359B2 true JP5752359B2 (ja) | 2015-07-22 |
Family
ID=44506407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010040502A Active JP5752359B2 (ja) | 2010-02-25 | 2010-02-25 | 体重増加抑制組成物及びこれを含む食品 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20120276081A1 (ja) |
EP (1) | EP2540316A4 (ja) |
JP (1) | JP5752359B2 (ja) |
KR (1) | KR20120123036A (ja) |
CN (1) | CN102711832A (ja) |
WO (1) | WO2011104971A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9259454B2 (en) | 2011-09-16 | 2016-02-16 | Kao Corporation | Solid composition |
JP5462343B2 (ja) * | 2011-12-15 | 2014-04-02 | 花王株式会社 | 固形状組成物 |
JP2014064505A (ja) * | 2012-09-25 | 2014-04-17 | Fujifilm Corp | 食品用組成物および脂質吸収抑制剤 |
CA2931157A1 (en) | 2013-11-19 | 2015-05-28 | OmniActive Health Technologies (Canada) Limited | Salacia compositions, methods of treatment by their administration, and methods of their preparation |
CN103977409A (zh) * | 2014-05-21 | 2014-08-13 | 吕健军 | 一种膳食补充剂组合物及其用于调控血糖的方法 |
AU2017319467B2 (en) * | 2016-09-02 | 2020-06-18 | Fujifilm Corporation | Livestock feed or livestock supplement, lactobacillus bacteria growth promoter, and lactobacillus bacteria growth promotion method |
CN111568985A (zh) * | 2020-05-03 | 2020-08-25 | 深圳简体美健康信息咨询有限公司 | 一种具有减肥功能的天然植物组合物及其制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW381025B (en) * | 1993-08-05 | 2000-02-01 | Hoffmann La Roche | Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor |
JP2646421B2 (ja) * | 1993-10-12 | 1997-08-27 | 日清製油株式会社 | 肥満予防剤 |
JPH11228430A (ja) * | 1998-02-20 | 1999-08-24 | Asahi Breweries Ltd | 脂肪分解促進剤 |
JP2000072687A (ja) * | 1998-08-26 | 2000-03-07 | Nippon Synthetic Chem Ind Co Ltd:The | α−グルコシダーゼ阻害剤 |
US6376682B1 (en) * | 2000-02-01 | 2002-04-23 | Takama System, Ltd. | Compound with α-glucosidase inhibiting action and method for producing the same |
CA2505140A1 (en) * | 2002-10-29 | 2004-05-21 | Council Of Scientific And Industrial Research | New alpha-glucosidase inhibitors from a natural source |
US7108869B2 (en) * | 2002-11-07 | 2006-09-19 | Access Business Group International Llc | Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors |
JP4316234B2 (ja) * | 2002-12-17 | 2009-08-19 | オルビス株式会社 | ダイエット用の食品 |
EP1674106B1 (en) * | 2003-10-06 | 2011-09-21 | Oryza Oil & Fat Chemical Co., Ltd | Dietetic composition |
CN1545939A (zh) * | 2003-11-28 | 2004-11-17 | 北京工商大学 | 一种以枳实提取物作为主要功能成分的减肥保健食品 |
JP2006223293A (ja) * | 2005-01-20 | 2006-08-31 | Iimono Okoku:Kk | ダイエット食品組成物 |
JP2007254440A (ja) * | 2006-03-27 | 2007-10-04 | Ihara Suisan Kk | 脂質代謝調節剤及び脂質代謝調節食品 |
MY147954A (en) * | 2006-05-26 | 2013-02-15 | Nestec Sa | Methods of use and nutritional compositions of touchi extract |
JP5638180B2 (ja) * | 2007-09-06 | 2014-12-10 | 富士フイルム株式会社 | サラシア属植物の抽出物とフラボノイドを含有する食品 |
JP5305500B2 (ja) * | 2008-01-30 | 2013-10-02 | 株式会社盛光 | リパーゼ阻害剤及びそれを含有する組成物 |
-
2010
- 2010-02-25 JP JP2010040502A patent/JP5752359B2/ja active Active
- 2010-12-03 CN CN2010800591321A patent/CN102711832A/zh active Pending
- 2010-12-03 KR KR1020127016198A patent/KR20120123036A/ko not_active Application Discontinuation
- 2010-12-03 EP EP10846634.3A patent/EP2540316A4/en not_active Withdrawn
- 2010-12-03 WO PCT/JP2010/071743 patent/WO2011104971A1/ja active Application Filing
- 2010-12-03 US US13/519,997 patent/US20120276081A1/en not_active Abandoned
-
2014
- 2014-02-20 US US14/185,129 patent/US20140186331A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20120123036A (ko) | 2012-11-07 |
WO2011104971A1 (ja) | 2011-09-01 |
JP2011173847A (ja) | 2011-09-08 |
EP2540316A1 (en) | 2013-01-02 |
CN102711832A (zh) | 2012-10-03 |
EP2540316A4 (en) | 2013-08-21 |
US20140186331A1 (en) | 2014-07-03 |
US20120276081A1 (en) | 2012-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5752359B2 (ja) | 体重増加抑制組成物及びこれを含む食品 | |
CN109475588A (zh) | 一种包含小豆栽培种的用于改善肌肉功能或用于增强运动能力的组合物 | |
CN105935364B (zh) | 用于预防或治疗非酒精性肝病的包含人参皂苷f2的组合物 | |
US10925918B2 (en) | Composition for food and fat absorption inhibitor | |
JP4432069B2 (ja) | 肥満抑制剤 | |
JP2008214191A (ja) | 肝中脂質蓄積抑制剤 | |
JP2006160710A (ja) | 糖尿病の予防・治療用組成物およびその有効成分を含む健康食品 | |
JP5969529B2 (ja) | 抗炎症剤 | |
KR101927399B1 (ko) | 지방간 치료용 또는 예방용 조성물 | |
JP6133005B2 (ja) | 一次胆汁酸及び二次胆汁酸生成調節剤 | |
AU2018313435A1 (en) | Blood flow improver | |
JP2005170836A (ja) | 海藻抽出物およびそれを含むリパーゼ阻害剤 | |
JP2003252775A (ja) | Nk細胞活性化剤 | |
KR100824704B1 (ko) | 지실 추출물을 유효성분으로 함유하는 비만 치료 및 예방용조성물 | |
JP2010043036A (ja) | 糖代謝促進剤 | |
JP5437672B2 (ja) | 血清中尿酸値の低減剤 | |
KR101079916B1 (ko) | 비만 증상의 개선 및 예방을 위한 육두구 추출물 함유 기능성식품 | |
JP2019180412A (ja) | 経口組成物 | |
KR20190086871A (ko) | 피조개 추출물을 유효성분으로 함유하는 알코올성 간 손상 억제용 조성물 | |
JP2019176828A (ja) | 経口組成物 | |
JP2005013123A (ja) | 食品組成物 | |
Nawaz et al. | The inhibitory effects of endophytic metabolites on glycated proteins under non-communicable disease conditions: A review | |
JP6454592B2 (ja) | アセチルコリンエステラーゼ阻害剤 | |
WO2010116425A1 (ja) | 大腸前がん病変抑制剤及び大腸がん予防剤 | |
JP2008174532A (ja) | 血糖値上昇抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120611 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140206 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150428 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150520 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5752359 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |